CoChat

Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites

Open access

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index; none of the 54 sources its claims cite is checked for support yet.

Abstract

Challenges in classifying recurrent Plasmodium vivax infections constrain surveillance of antimalarial efficacy and transmission. Recurrent infections may arise from activation of dormant liver stages (relapse), blood-stage treatment failure (recrudescence) or reinfection. Molecular inference of familial relatedness (identity-by-descent or IBD) can help resolve the probable origin of recurrences. As whole genome sequencing of P. vivax remains challenging, targeted genotyping methods are needed for scalability. We describe a P. vivax marker discovery framework to identify and select panels of microhaplotypes (multi-allelic markers within small, amplifiable segments of the genome) that can accurately capture IBD. We evaluate panels of 50–250 microhaplotypes discovered in a global set of 615 P. vivax genomes. A candidate global 100-microhaplotype panel exhibits high marker diversity in the Asia-Pacific, Latin America and horn of Africa (median H E = 0.70–0.81) and identifies 89% of the polyclonal infections detected with genome-wide datasets. Data simulations reveal lower error in estimating pairwise IBD using microhaplotypes relative to traditional biallelic SNP barcodes. The candidate global panel also exhibits high accuracy in predicting geographic origin and captures local infection outbreak and bottlenecking events. Our framework is open-source enabling customised microhaplotype discovery and selection, with potential for porting to other species or data resources.

Overview

CoChat Summary

TL;DR

The paper describes an open-source framework to discover and select *Plasmodium vivax* microhaplotype panels that capture identity-by-descent (IBD) for classifying recurrent infections and for spatio-temporal surveillance. A candidate global 100-microhaplotype panel shows high diversity, better IBD estimation than traditional biallelic SNP barcodes, and utility for geographic origin prediction and outbreak detection.

Key findings

  • A candidate global 100-microhaplotype panel exhibited high marker diversity in the Asia-Pacific, Latin America and horn of Africa (median HE = 0.70–0.81) and identified 89% of the polyclonal infections detected with genome-wide datasets.
  • In simulations, the high-diversity microhaplotype panel had lower error in pairwise IBD estimation than a random microhaplotype panel and the 38-SNP Broad barcode; it was the only panel consistently keeping RMSE below 0.1 in all subpopulations even when r = 0.5, and all (100%) estimates of r = 0.5 had 95% CIs between 0.1 and 0.8.
  • Among 14 paired primary/recurrent infections, genome-wide IBD classified 11 as clones (IBD ≥ 0.95), 1 as a distant relative (0.05 ≤ IBD < 0.25), and 2 as strangers (IBD < 0.05); microhaplotype-based estimates correlated highly with genome-wide IBD (rho = 0.790), with 13/14 concordant recurrence classifications and one pair reclassified from stranger to distant relative.
  • The 494 microhaplotype SNPs had median MCC greater than or equal to the 38-SNP Broad barcode, GEO33 and GEO50 in 21/21 countries for country-of-origin prediction; GEO55 was higher in 3/21 countries but lower in 4/21, and median MCC exceeded 0.9 in 19/21 countries. Increasing panel size improved IBD accuracy greatly between 50 and 100 microhaplotypes, with diminishing returns above 100.

Methods

  • Marker discovery used 615 high-quality, likely monoclonal *P. vivax* genomes from MalariaGEN Pv4 (filtered from 1,816 isolates across 17 countries), identifying 13,084 candidate biallelic SNPs and 3,830 microhaplotype candidate heterozygome windows; panels of 50–250 microhaplotypes were selected from 200 bp windows with 3–10 SNPs, even spacing, and high heterozygosity.
  • Panels were evaluated with simulated data using paneljudge (data-generating r = 0, 0.25, 0.5, 0.75, 1.0; 100 haploid genotype pairs; 95% CIs and RMSE) and with real data using hmmIBD on genome-wide versus microhaplotype SNPs, including 14 recurrent infection pairs and an independent non-Pv4 dataset of 324 high-quality monoclonal samples (IBD analyses restricted to 289 samples from 4 regional groups).
  • Additional analyses assessed population diversity, within-host complexity of infection with THE REAL McCOIL, spatial clustering by PCoA and IBD networks, and country-of-origin prediction with a Bi-Allele Likelihood classifier.

Limitations

  • The paper states that simulated panel evaluation was highly idealised, with data simulated under the same model used for estimation; the impact of mis-specified allele frequencies, mis-classified multiclonal infections, and genotyping errors or failures was not evaluated.
  • The paper states that available genomic data contained no infection pairs with IBD around 50% (siblings), the relationship simulations predicted to be hardest to determine accurately, and that the number of genomic pairs was limited by difficulty obtaining enough DNA and high-quality sequence from recurrent infections.
  • The paper states that some global regions are not well represented in Pv4 (Africa, the Indian subcontinent/West Asia, Central and South America), making it unclear how well the microhaplotypes capture IBD there; the independent dataset also had higher missing calls at the 494 microhaplotype SNPs (median 17%, range 0–50%) than Pv4 (median 0%, mean 2.5%, range 0–34%), and some microhaplotypes may be subject to site-specific selective pressure.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-024-51015-3

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Microhaplotype discovery pipeline. Panel (a) provides an overview of the marker selection process. Criteria for selecting samples, variants, and windows for potential microhaplotype candidate windows result in a total of 5460 windows (200 bp). The MalariaGEN Pv4 dataset was filtered to use only high-quality monoclonal samples (Fws ≥ 0.95) that had at least 50% of the core genome positions callable. SNP variants from this sample subset were then identified as biallelic, have low genotype missingness (<0.1), had high global minor allele frequencies (MAF ≥ 0.1), and FILTER = PASS in the MalariaGEN dataset, resulting in 13,084 total SNPs. The core genome was then scanned in coding regions for all 200 bp windows in which > 3 of the identified variants were found and filtered for high diversity (global heterozygosity ≥0.5). Panel (b) provides a schematic representation of microhaplotypes with 3 SNPs. Microhaplotypes leverage SNP information content in small-windowed regions of the genome to provide a high-resolution reconstruction of the parasite genome. Three high-diversity SNPs in a single microhaplotype can have as many as 8 distinct combinations of alleles which, when combined with 100 or more microhaplotypes across the genome, results in high discriminatory power to characterise relatedness. c Manhattan plot of the P. vivax windows identified across the genome, showing the chromosomal distribution of all windows identified in the global set of high-quality, independent monoclonal infections with at least 1 SNP. Each point is an identified window, with the size increasing as the number of SNPs within the window increases. Potential microhaplotype regions are well distributed across the 14 chromosomes. The microhaplotypes with the highest SNP densities tend to be located at the ends of the chromosomes. Note, microhaplotypes were selected only from the core regions of the genome i.e., excluding highly diverse telomeric, sub-telomeric and centromere regions where sequence reads could not be mapped accurately (see Pv4 data resource for further details on core regions).
Fig. 1 Microhaplotype discovery pipeline. Panel (a) provides an overview of the marker selection process. Criteria for selecting samples, variants, and windows for potential microhaplotype candidate windows result in a total of 5460 windows (200 bp). The MalariaGEN Pv4 dataset was filtered to use only high-quality monoclonal samples (Fws ≥ 0.95) that had at least 50% of the core genome positions callable. SNP variants from this sample subset were then identified as biallelic, have low genotype missingness (<0.1), had high global minor allele frequencies (MAF ≥ 0.1), and FILTER = PASS in the MalariaGEN dataset, resulting in 13,084 total SNPs. The core genome was then scanned in coding regions for all 200 bp windows in which > 3 of the identified variants were found and filtered for high diversity (global heterozygosity ≥0.5). Panel (b) provides a schematic representation of microhaplotypes with 3 SNPs. Microhaplotypes leverage SNP information content in small-windowed regions of the genome to provide a high-resolution reconstruction of the parasite genome. Three high-diversity SNPs in a single microhaplotype can have as many as 8 distinct combinations of alleles which, when combined with 100 or more microhaplotypes across the genome, results in high discriminatory power to characterise relatedness. c Manhattan plot of the P. vivax windows identified across the genome, showing the chromosomal distribution of all windows identified in the global set of high-quality, independent monoclonal infections with at least 1 SNP. Each point is an identified window, with the size increasing as the number of SNPs within the window increases. Potential microhaplotype regions are well distributed across the 14 chromosomes. The microhaplotypes with the highest SNP densities tend to be located at the ends of the chromosomes. Note, microhaplotypes were selected only from the core regions of the genome i.e., excluding highly diverse telomeric, sub-telomeric and centromere regions where sequence reads could not be mapped accurately (see Pv4 data resource for further details on core regions).CC BY · PubMed Central
Fig. 2 Marker property outputs within the discovery pipeline. Panel (a) illustrates an example marker selection plot output from the marker selection framework. Panel (b) illustrates examples of marker heterozygosity and distance distributions output from the marker selection framework. Panel (c) illustrates the chromosome distribution of three panels (two of which were selected within the framework) that were evaluated for their capacity to reconstruct parasite relatedness. Two new microhaplotype panels were created from the microhaplotype discovery pipeline, named “Random mhaps” plotted in orange, and “High-diversity mhaps” plotted in purple. These two panels were selected to have 100 microhaplotype markers using windows that were well-spaced and had between 3–10 SNPS, with even distribution across all 14 chromosomes and a minimum diversity with heterozygosity ≥0.65. The markers for the Random mhaps panel were selected randomly without optimisation, while the High-diversity mhaps panel were optimised to have the highest heterozygosity possible in each region. These two high-resolution panels were compared to the commonly used biallelic 42-SNP panel, named “BR38” in green. Only 38 markers of this panel are considered informative and included in this representation.
Fig. 2 Marker property outputs within the discovery pipeline. Panel (a) illustrates an example marker selection plot output from the marker selection framework. Panel (b) illustrates examples of marker heterozygosity and distance distributions output from the marker selection framework. Panel (c) illustrates the chromosome distribution of three panels (two of which were selected within the framework) that were evaluated for their capacity to reconstruct parasite relatedness. Two new microhaplotype panels were created from the microhaplotype discovery pipeline, named “Random mhaps” plotted in orange, and “High-diversity mhaps” plotted in purple. These two panels were selected to have 100 microhaplotype markers using windows that were well-spaced and had between 3–10 SNPS, with even distribution across all 14 chromosomes and a minimum diversity with heterozygosity ≥0.65. The markers for the Random mhaps panel were selected randomly without optimisation, while the High-diversity mhaps panel were optimised to have the highest heterozygosity possible in each region. These two high-resolution panels were compared to the commonly used biallelic 42-SNP panel, named “BR38” in green. Only 38 markers of this panel are considered informative and included in this representation.CC BY · PubMed Central
Fig. 3 Confidence intervals around infection relatedness estimates using 100 microhaplotype-based simulations. The 95% confidence intervals (CI, shaded regions) surrounding the mean are based on data simulated using 5 data-generating relatedness parameters, r. Data are presented on 3 marker panels: High-diversity microhaplotype panel (purple), Random-SNP microhaplotype panel (orange), and 38 Broad barcode biallelic SNPs (green). Separate plots are provided for each r (from 0.01–0.99) and geographic region; AF (Africa), ESEA (East Southeast Asia), MSEA (Maritime Southeast Asia), OCE (Oceania), SAM (South America), WAS (West Asia) and WSEA (West Southeast Asia). The data simulations were conducted on allele frequency data input from n = 34 (AF) n = 151 (ESEA), n = 59 (MSEA), n = 120 (OCE), n = 135 (SAM), n = 31 (WAS), and n = 85 (WSEA) independent, monoclonal samples.
Fig. 3 Confidence intervals around infection relatedness estimates using 100 microhaplotype-based simulations. The 95% confidence intervals (CI, shaded regions) surrounding the mean are based on data simulated using 5 data-generating relatedness parameters, r. Data are presented on 3 marker panels: High-diversity microhaplotype panel (purple), Random-SNP microhaplotype panel (orange), and 38 Broad barcode biallelic SNPs (green). Separate plots are provided for each r (from 0.01–0.99) and geographic region; AF (Africa), ESEA (East Southeast Asia), MSEA (Maritime Southeast Asia), OCE (Oceania), SAM (South America), WAS (West Asia) and WSEA (West Southeast Asia). The data simulations were conducted on allele frequency data input from n = 34 (AF) n = 151 (ESEA), n = 59 (MSEA), n = 120 (OCE), n = 135 (SAM), n = 31 (WAS), and n = 85 (WSEA) independent, monoclonal samples.CC BY · PubMed Central
Fig. 4 Comparative diversity between the High-diversity microhaplotype panel and the 38-SNP Broad Barcode. Panel (a) presents heterozygosity measures and panel (b) presents effective cardinality scores in n = 615 high-quality biologically independent monoclonal samples by panel and region. Each boxplot presents the median, interquartile range and min and max value for the hetereozygosity panel (a) and effective cardinality (b). Panel labels; 38-SNP Broad barcode (BR38) and High-diversity microhaplotype panel (MHAP-3_10). Regional labels; Africa (AF), East Southeast Asia (ESEA), Maritime Southeast Asia (MSEA), Oceania (OCE), South America (SAM), West Asia (WAS) and West Southeast Asia (WSEA).
Fig. 4 Comparative diversity between the High-diversity microhaplotype panel and the 38-SNP Broad Barcode. Panel (a) presents heterozygosity measures and panel (b) presents effective cardinality scores in n = 615 high-quality biologically independent monoclonal samples by panel and region. Each boxplot presents the median, interquartile range and min and max value for the hetereozygosity panel (a) and effective cardinality (b). Panel labels; 38-SNP Broad barcode (BR38) and High-diversity microhaplotype panel (MHAP-3_10). Regional labels; Africa (AF), East Southeast Asia (ESEA), Maritime Southeast Asia (MSEA), Oceania (OCE), South America (SAM), West Asia (WAS) and West Southeast Asia (WSEA).CC BY · PubMed Central
Fig. 5 Genome-wide FWS distribution by microhaplotype-based complexity of infection (COI). Data from n = 922 high-quality biologically independent samples from Africa (AF), East Southeast Asia (ESEA), Maritime Southeast Asia (MSEA), Oceania (OCE), South America (SAM), West Asia (WAS) and West Southeast Asia (WSEA). Panel (a) provides boxplots illustrating the distribution of genome wide FWS scores in each of the monoclonal and polyclonal infection subsets as determined by THEREALMcCOIL analysis of the SNPs in the 100 microhaplotypes using the proportional function. Each boxplot presents the median, interquartile range and min and max of the FWS. In all geographic regions, the median genome-wide FWS scores are closer to 1 (little to no within-host diversity) in the infections defined as monoclonal. Panel (b) illustrates the correlation between genome-wide FWS and microhaplotype-based COI estimates; a trend of decreasing COI is observed with increasing FWS (i.e., decreasing within-host diversity).
Fig. 5 Genome-wide FWS distribution by microhaplotype-based complexity of infection (COI). Data from n = 922 high-quality biologically independent samples from Africa (AF), East Southeast Asia (ESEA), Maritime Southeast Asia (MSEA), Oceania (OCE), South America (SAM), West Asia (WAS) and West Southeast Asia (WSEA). Panel (a) provides boxplots illustrating the distribution of genome wide FWS scores in each of the monoclonal and polyclonal infection subsets as determined by THEREALMcCOIL analysis of the SNPs in the 100 microhaplotypes using the proportional function. Each boxplot presents the median, interquartile range and min and max of the FWS. In all geographic regions, the median genome-wide FWS scores are closer to 1 (little to no within-host diversity) in the infections defined as monoclonal. Panel (b) illustrates the correlation between genome-wide FWS and microhaplotype-based COI estimates; a trend of decreasing COI is observed with increasing FWS (i.e., decreasing within-host diversity).CC BY · PubMed Central
Fig. 6 Spatial trends in P. vivax connectivity using microhaplotypes versus genomic data. Panels (a) and (b) present PCoA plots generated with whole genome sequencing (WGS) and High-diversity SNP microhaplotype data on n = 615 high-quality biologically independent monoclonal isolates from Pv4. The WGS data was generated at 574,604 biallelic SNPs (with minimum allele count ≥2), with PC1 (49.9%) and PC2 (17.5%) displayed. The microhaplotype plot also presents PC1 (46.4%) and PC2 (25.3%). The combinations of PC1 and PC2 provide marked separation of all 7 regional groups in both the WGS and microhaplotype data sets. Panels (c) and (d) present WGS and microhaplotype-based IBD infection networks in Malaysia. The network plots were generated at a set of 224,612 SNPs (WGS) and the High-diversity SNP microhaplotype panel in single clone Malaysian infections (n = 57) at a connectivity threshold of minimum IBD 0.5 (siblings or greater relatedness). Infections are colour-coded according to sub-structure definitions based on previously described ADMIXTURE analysis with genomic data30. Infections defined as “New” (purple) were not available in the previous analysis. The clustering patterns of the WGS and microhaplotype-based data are highly consistent; both data sets capture high connectivity amongst the K2 outbreak strains, a distinct K3 sub-population, and divergent K4 infections27. The new infections appear to derive from across the different sub-populations.
Fig. 6 Spatial trends in P. vivax connectivity using microhaplotypes versus genomic data. Panels (a) and (b) present PCoA plots generated with whole genome sequencing (WGS) and High-diversity SNP microhaplotype data on n = 615 high-quality biologically independent monoclonal isolates from Pv4. The WGS data was generated at 574,604 biallelic SNPs (with minimum allele count ≥2), with PC1 (49.9%) and PC2 (17.5%) displayed. The microhaplotype plot also presents PC1 (46.4%) and PC2 (25.3%). The combinations of PC1 and PC2 provide marked separation of all 7 regional groups in both the WGS and microhaplotype data sets. Panels (c) and (d) present WGS and microhaplotype-based IBD infection networks in Malaysia. The network plots were generated at a set of 224,612 SNPs (WGS) and the High-diversity SNP microhaplotype panel in single clone Malaysian infections (n = 57) at a connectivity threshold of minimum IBD 0.5 (siblings or greater relatedness). Infections are colour-coded according to sub-structure definitions based on previously described ADMIXTURE analysis with genomic data30. Infections defined as “New” (purple) were not available in the previous analysis. The clustering patterns of the WGS and microhaplotype-based data are highly consistent; both data sets capture high connectivity amongst the K2 outbreak strains, a distinct K3 sub-population, and divergent K4 infections27. The new infections appear to derive from across the different sub-populations.CC BY · PubMed Central
Fig. 7 Comparison of country prediction performance between SNP panels. Comparisons were undertaken between the 494 SNPs in the High-diversity microhaplotype panel (MHAP-3_10), the 38-SNP Broad barcode (BR38), and the 33-, 50- and 55-SNP GEO panels (GEO33, GEO50 and GEO55 respectively). The boxplots present the Mathews correlation coefficient (MCC) scores from 500 repeats with stratified 10-fold cross validation for each SNP set using the Bi-Allele Likelihood classifier31. Each boxplot provides the median, interquartile range and min and max MCC for the given country and panel. Country labels are provided on the y-axis. Each bar presents the median, interquartile range and minimum and maximum MCC for the given country and model. The analyses were based on n = 799 biologically independent samples from 21 countries (each with n ≥ 4 samples).
Fig. 7 Comparison of country prediction performance between SNP panels. Comparisons were undertaken between the 494 SNPs in the High-diversity microhaplotype panel (MHAP-3_10), the 38-SNP Broad barcode (BR38), and the 33-, 50- and 55-SNP GEO panels (GEO33, GEO50 and GEO55 respectively). The boxplots present the Mathews correlation coefficient (MCC) scores from 500 repeats with stratified 10-fold cross validation for each SNP set using the Bi-Allele Likelihood classifier31. Each boxplot provides the median, interquartile range and min and max MCC for the given country and panel. Country labels are provided on the y-axis. Each bar presents the median, interquartile range and minimum and maximum MCC for the given country and model. The analyses were based on n = 799 biologically independent samples from 21 countries (each with n ≥ 4 samples).CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 38 Not checked · 107 Own results and interpretations

75 more claims

Create a free account to see all 145 claims and to verify the 53 references still open.

See all claims — free account
  • Probably not a substantial claim. 36
  • It may state two separate claims as one. 38

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 56 references

Cited by

See all 30

Metadata

Authors
Siegel, S. V., Trimarsanto, H., Amato, R., Murie, K., Taylor, A. R., Sutanto, E., Kleinecke, M., Whitton, G., Watson, J. A., Imwong, M., Assefa, A., Rahim, A. G., Nguyen, H. C., Tran, T. H., Green, J. A., Koh, G. C. K. W., White, N. J., Day, N., Kwiatkowski, D. P., Rayner, J. C., Price, R. N., & Auburn, S.
Affiliations
  • Wellcome Sanger Institute (GB)
  • Eijkman Institute for Molecular Biology (ID)
  • Institut Pasteur (FR)
  • Charles Darwin University (AU)
  • University of Oxford (GB)
  • Mahidol University (TH)
  • University of North Carolina at Chapel Hill (US)
  • Oxford University Clinical Research Unit (VN)
  • GlaxoSmithKline (United Kingdom) (GB)
  • Northwick Park Hospital (GB)
  • University of Cambridge (GB)
Corresponding author
Auburn, Sarah
Venue
Nature Communications
Published
2024-08-08
Volume
15
Issue
1
Pages
6757-6757
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4401422291
Cited by
30
References
56
Citations by year
2026: 12 · 2025: 11 · 2024: 5
FWCI
7.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • medRxiv (submittedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • Oxford University Research Archive (ORA) (University of Oxford) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • HAL (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • PubMed (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Bill and Melinda Gates Foundation (INV-043618, OPP1054404)
  • Department of Health | National Health and Medical Research Council (APP2001083)
  • Wellcome Trust (206194, 204911, 206194/Z17/Z, ICRG GR071614MA)
  • Medical Research Council and UK Department for International Development
  • U.S. Department of Health & Human Services | National Institutes of Health (R01AI137154)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic diversity and population structure
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Forensic and Genetic Research
Keywords
Plasmodium vivax, microhaplotypes, identity by descent, recurrent malaria, relapse, recrudescence, reinfection, molecular surveillance, marker discovery, polyclonal infection, antimalarial drug efficacy, targeted genotyping
MeSH terms
Genotype, Haplotypes, Humans, Plasmodium vivax, Recurrence, Malaria, Vivax, Genome, Protozoan, Polymorphism, Single Nucleotide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites. https://app.cochat.ai/papers/10.1038/s41467-024-51015-3
The paper
Siegel, S. V., Trimarsanto, H., Amato, R., Murie, K., Taylor, A. R., Sutanto, E., Kleinecke, M., Whitton, G., Watson, J. A., Imwong, M., Assefa, A., Rahim, A. G., Nguyen, H. C., Tran, T. H., Green, J. A., Koh, G. C. K. W., White, N. J., Day, N., Kwiatkowski, D. P., . . . Auburn, S. (2024). Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites. Nature Communications. https://doi.org/10.1038/s41467-024-51015-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.